Hypothermia-induced platelet aggregation: No effect of aprotinin (Trasylol®) but inhibition by eptifibatide (Integrilin®)

Thoracic and Cardiovascular Surgeon

Volumn 53, Issue 2, 2005, Pages 80-84

  Straub, A ^a,b   Azevedo, R ^a   Beierlein, W ^a   Wendel, H P ^a   Scheule, A M ^a   Ziemer, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Aprotinin; GP IIb IIIa inhibition; Hypothermia; Platelets

Indexed keywords

ANTIBODY; ANTIBODY PAC1; APROTININ; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; CARDIOPULMONARY BYPASS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN TISSUE; INDUCED HYPOTHERMIA; ISCHEMIA; MALE; MICROVASCULATURE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; VOLUNTEER;

APROTININ; BLOOD PLATELETS; BLOOD SPECIMEN COLLECTION; COLD; FLOW CYTOMETRY; HUMANS; HYPOTHERMIA; MALE; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 17444367990     PISSN: 01716425     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830501     Document Type: Article

References (23)

1. Landis RC, Haskard DO, Taylor KM. New antiinflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg 2001; 72: S1808-1813
2. Westaby S, Forni A, Dunning J et al. Aprotinin and bleeding in profoundly hypothermic perfusion. Eur J Cardiothorac Surg 1994; 8: 82-86
3. Sundt TM 3rd, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993; 55: 1418-1424
4. Saffitz JE, Stahl DJ, Sundt TM, Wareing TH, Kouchoukos NT. Disseminated intravascular coagulation after administration of aprotinin in combination with deep hypothermic circulatory arrest. Am J Cardiol 1993; 72: 1080-1082
5. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-231
6. Dyke CM, Bhatia D, Lorenz TJ et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using Integrelin therapy. Ann Thorac Surg 2000; 70: 866-871; discussion 871-872
7. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-138
8. Jy W, Horstman LL, Park H, Mao WW, Valant P, Ahn YS. Platelet aggregates as markers of platelet activation: characterization of flow cytometric method suitable for clinical applications. Am J Hematol 1998; 57: 33-42
9. Peter K, Straub A, Kohler B et al. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 1999; 84: 519-524
10. Hall MW, Goodman PD, Alston SM, Solen KA. Hypothermia-induced platelet aggregation in heparinized flowing human blood: identification of a high responder subpopulation. Am J Hematol 2002; 69: 45-55
11. Faraday N, Rosenfeld BA. In vitro hypothermia enhances platelet GPIIb-IIIa activation and P-selectin expression. Anesthesiology 1998; 88: 1579-1585
12. Gurbel PA, Galbut B, Bliden KP et al. Effect of eptifibatide for acute coronary syndromes: rapid versus late administration - therapeutic yield on platelets (The EARLY Platelet Substudy). J Thromb Thrombolysis 2002; 14: 213-219
13. Dalby M, Montalescot G, Bal dit Sollier C et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol 2004; 43: 162-168
14. Taub R, Could RJ, Garsky VM et al. A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen. J Biol Chem 1989; 264: 259-265
15. Bizzarri F, Scolletta S, Tucci E et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 122: 1181-1185
16. Koster A, Chew DP, Kuebler W et al. Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass. Am J Cardiol 2003; 91: 346-347
17. Genoni M, Zeller D, Bertel O, Maloigne M, Turina M. Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery. J Thorac Cardiovasc Surg 2001; 122: 630-632
18. Alton KB, Kosoglou T, Baker S, Affrime MB, Cayen MN, Patrick JE. Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin Ther 1998; 20: 307-323
19. Barrett JS, Murphy G, Peerlinck K et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994; 56: 377-388
20. Suzuki Y, Hillyer P, Miyamoto S et al. Integrilin prevents prolonged bleeding times after cardiopulmonary bypass. Ann Thorac Surg 1998; 66: 373-381
21. Hiramatsu Y, Gikakis N. Anderson HL 3rd et al. Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1997; 113: 182-193
22. Royston D. Pro: aprotinin should be used in patients undergoing hypothermic circulatory arrest. J Cardiothorac Vase Anesth 2001; 15: 121-125
23. Smith CR, Spanier TB. Aprotinin in deep hypothermic circulatory arrest. Ann Thorac Surg 1999; 68: 278-286